Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 912-918

  Advani, Ranjana H ^a   Horning, Sandra J ^a   Hoppe, Richard T ^a   Daadi, Sarah ^a   Allen, John ^a   Natkunam, Yasodha ^a   Bartlett, Nancy L ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HODGKIN DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84899637852     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2069     Document Type: Article

References (24)

1. Stein H: Hodgkin lymphoma, in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008, pp 321-334
2. Nogová L, Reineke T, Brillant C, et al: Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439, 2008 (Pubitemid 351171696)
3. Diehl V, Sextro M, Franklin J, et al: Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17:776-783, 1999 (Pubitemid 29109305)
4. NCCN guideline updates: Hodgkin lymphoma v. 2.2013. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#hodgkin
5. Franklin J, Tesch H, Hansmann ML, et al: Lymphocyte predominant Hodgkin's disease: Pathology and clinical implication. Ann Oncol 9:S39-S44, 1998 (suppl 5)
6. Tsai HK, Mauch PM: Nodular lymphocytepredominant Hodgkin lymphoma. Semin Radiat Oncol 17:184-189, 2007
7. Anagnostopoulos I, Hansmann ML, Franssila K, et al: European Task Force on Lymphoma Project on Lymphocyte Predominance Hodgkin Disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96:1889-1899, 2000 (Pubitemid 30661074)
8. Ekstrand BC, Lucas JB, Horwitz SM, et al: Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood 101:4285-4289, 2003 (Pubitemid 36857790)
9. Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088-1095, 2005 (Pubitemid 46202263)
10. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-sponsored international working group. J Clin Oncol 17:1244, 1999
11. Simon R: Design and analysis of clinical trials, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 521-538
12. Chen RC, Chin MS, Ng AK, et al: Earlystage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, singleinstitution series with long follow-up. J Clin Oncol 28:136-141, 2010
13. Nogová L, Reineke T, Eich HT, et al: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-1687, 2005 (Pubitemid 41510144)
14. Savage KJ, Skinnider B, Al-Mansour M, et al: Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118:4585-4590, 2011
15. Eichenauer DA, Fuchs M, Pluetschow A, et al: Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 118:4363-4365, 2011
16. Fanale MA, Lai C-M, McLaughlin P, et al: Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood 116, 2010 (abstr 2812)
17. Canellos GP, Mauch P: What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol 28:e8, 2010
18. Schulz H, Rehwald U, Morschhauser F, et al: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109-111, 2008
19. Wickert RS, Weisenburger DD, Tierens A, et al: Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 86:2312-2320, 1995
20. Greiner TC, Gascoyne RD, Anderson ME, et al: Nodular lymphocyte- predominant Hodgkin's disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 88:657-666, 1996 (Pubitemid 26240397)
21. Ohno T, Huang JZ, Wu G, et al: The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual: Direct demonstration by single cell analysis. Am J Clin Pathol 116:506-511, 2001 (Pubitemid 34450284)
22. Biasoli I, Stamatoullas A, Meignin V, et al: Nodular, lymphocyte-predominant Hodgkin lymphoma: A long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 116:631-639, 2010
23. Al-Mansour M, Connors JM, Gascoyne RD, et al: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 28:793-799, 2010
24. Xing KH, Savage KJ: Modern management of lymphocyte predominant Hodgkin lymphoma. Br J Haematol 161:316-329, 2013